Can alteplase (tPA) be administered to this patient with sinus bradycardia (heart rate 57 bpm) who cannot undergo primary percutaneous coronary intervention within the recommended time window and has no absolute contraindications to fibrinolysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, administer alteplase to this patient with sinus bradycardia (HR 57 bpm) if primary PCI cannot be achieved within the recommended time window and there are no absolute contraindications to fibrinolysis.

Sinus bradycardia at 57 bpm is NOT a contraindication to fibrinolytic therapy for STEMI. The presence of bradycardia does not appear in either the absolute or relative contraindication lists for fibrinolysis 1.

Clinical Decision Framework

Step 1: Verify Indication for Reperfusion

  • Symptoms present <12 hours with persistent ST-segment elevation 1, 2
  • If primary PCI cannot be performed within 2 hours from first medical contact, fibrinolytic therapy is indicated 1

Step 2: Screen for Absolute Contraindications

The following are absolute contraindications that would preclude alteplase use 1:

  • Any prior intracranial hemorrhage
  • Known structural cerebral vascular lesion
  • Known malignant intracranial neoplasm
  • Ischemic stroke within 3 months (except acute ischemic stroke <4.5 hours)
  • Suspected aortic dissection
  • Active bleeding or bleeding diathesis
  • Significant closed-head or facial trauma within 3 months
  • Intracranial/intraspinal surgery within 2 months
  • Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg unresponsive to therapy)

Step 3: Assess Relative Contraindications

Relative contraindications require clinical judgment but do not absolutely prohibit treatment 1:

  • History of chronic, severe, poorly controlled hypertension
  • Significant hypertension on presentation (SBP >180 or DBP >110 mmHg)
  • History of prior ischemic stroke >3 months
  • Traumatic or prolonged CPR (>10 minutes)
  • Major surgery (<3 weeks)
  • Recent internal bleeding (2-4 weeks)
  • Pregnancy
  • Active peptic ulcer
  • Oral anticoagulant therapy

Notably absent from both lists: bradycardia, heart rate parameters, or conduction abnormalities.

Recommended Alteplase Regimen

Use a fibrin-specific agent 2. The 2025 ACC/AHA guidelines provide specific dosing 1:

Alteplase (tPA) Dosing:

  • Adults ≥67 kg: 100 mg total

    • 15 mg IV bolus
    • 50 mg IV over 30 minutes
    • 35 mg IV over next 60 minutes
  • Adults <67 kg:

    • 15 mg IV bolus
    • 0.75 mg/kg IV (max 50 mg) over 30 minutes
    • 0.5 mg/kg IV (max 35 mg) over next 60 minutes

Essential Adjunctive Therapy

Administer concurrently 2:

  • Aspirin: Oral or IV as soon as possible
  • Clopidogrel: In addition to aspirin
  • Anticoagulation: Enoxaparin IV followed by subcutaneous (preferred over unfractionated heparin) OR weight-adjusted UFH bolus followed by infusion

Post-Fibrinolysis Management

Immediate transfer to PCI-capable center is mandatory 2 for all patients after fibrinolysis, with specific timing based on clinical response:

  • Emergency angiography/PCI: If heart failure or shock develops 2
  • Rescue PCI immediately: If fibrinolysis fails (<50% ST-segment resolution at 60-90 minutes) or hemodynamic/electrical instability occurs 2
  • Routine angiography/PCI: Between 2-24 hours after successful fibrinolysis 2

Critical Caveats Regarding Bradycardia

The bradycardia itself warrants attention but should not delay fibrinolysis:

  1. Monitor for progression: Sinus bradycardia at 57 bpm may be physiologic, medication-related, or represent inferior STEMI with vagal tone
  2. Have atropine ready: If symptomatic bradycardia develops (hypotension, altered mental status, chest pain, acute heart failure)
  3. Prepare for temporary pacing: If high-degree AV block develops during or after fibrinolysis
  4. Watch for reperfusion arrhythmias: Accelerated idioventricular rhythm or transient bradycardia may indicate successful reperfusion

Bleeding Risk Considerations

The most recent evidence shows alteplase carries a higher risk of intracranial hemorrhage compared to streptokinase 3, 4. However, this must be weighed against mortality benefit. The 2025 guidelines acknowledge this trade-off but maintain the Class I recommendation for fibrinolysis when PCI is not timely 1.

The accelerated alteplase regimen demonstrated survival advantage that persists at 1 year, with an estimated cost of $32,678 per year of life saved compared to streptokinase 4.

Time-Critical Nature

Initiate fibrinolysis as soon as possible after STEMI diagnosis, preferably in the pre-hospital setting 2. A 50% reduction in mortality is expected if treatment starts within the first hour 5. Benefit persists up to 12 hours from symptom onset 1, 4.

The presence of sinus bradycardia should prompt ECG monitoring with defibrillator capacity 2 but must not delay definitive reperfusion therapy when indicated and not contraindicated.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.